Could pedaling backward help heart and lung patients get stronger?
NCT ID NCT07042750
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study investigates whether eccentric cycling—where the pedals resist the rider's effort, similar to walking downhill—can improve exercise capacity in people with heart or lung conditions. Unlike normal cycling, eccentric cycling demands less oxygen, which may allow patients to train harder with less strain. The trial compares eccentric cycling added to standard pulmonary rehabilitation against standard care alone in 22 adults with cardiopulmonary disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- eccentric cycling exercise
- What this could lead to
- If it works, eccentric cycling could become a standard part of pulmonary rehab, helping patients exercise more with less strain on the heart and lungs.
- What could go wrong
- This is a small, early-stage study with only 22 participants, so results may not apply to all patients. The benefits seen in previous studies may not hold up in this broader group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
22 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with PVD, either PAH or CTEPH via right heart catheterization, according to recent guidelines \[9\] * Diagnosed with a cardiopulmonary disease as indication for a pulmonary rehabilitation * Stable medication for at least 1 month * Age 18years to 85 years * No resting hypoxemia (PaO2 \>7.3 kPa) * Medical indication to prescibe a pulmonary rehabilitation Exclusion Criteria: * Any co-morbidity that limits the patient to participate the full rehabilitation * Enrollments in other trials with active treatments * Language barriers that limits the patient to participate in the rehabilitation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic left heart failure are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Klinik Barmelweid
Barmelweid, 5017, Switzerland
-
Universitätsspital Zürich
Zurich, 8092, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The role of volumetric High-Resolution computed tomography (HRCT) of the chest in the assessment of patients with stable chronic obstructive pulmonary disease (COPD)
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Can a common gout pill shield hearts after stents?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- Can a simple blood test flag hidden heart risks after stenting?
- App alerts COPD patients when their inhalers may be out of date